Aspirin Exacerbated Respiratory Disease Market

Aspirin Exacerbated Respiratory Disease Market

The global aspirin exacerbated respiratory disease market size is expected to reach US$ 8.7 Billion in 2032 and exhibit growth at a CAGR of 4.9% in the forecast period from 2022 to 2032. As per the report, sales of treatment options for aspirin exacerbated respiratory disease is likely to exceed US$ 3.1 Billion in 2022. The increasing number of research and development activities to discover novel treatment options are anticipated to boost the market.

Report Attribute	Details
Aspirin Exacerbated Respiratory Disease Market Estimated Base Year Value (2021)	US$ 2.5 Billion
Aspirin Exacerbated Respiratory Disease Market Expected Market Value (2022)	US$ 3.1 Billion
Aspirin Exacerbated Respiratory Disease Market Anticipated Forecast Value (2032)	US$ 8.7 Billion
Aspirin Exacerbated Respiratory Disease Market Projected Growth Rate (2022-2032)	4.9% CAGR

Aspirin-exacerbated respiratory disease or Samter’s Triad is a chronic medical condition that includes three clinical features, namely, sensitivity to aspirin, sinus disease with recurrent nasal polyps, and asthma. Signs and symptoms of this disease do not usually show up until an individual reaches their 30s or 40s.

Some of the signs and symptoms include sneezing, difficulty breathing, runny nose, coughing, or wheezing. Some people living with aspirin-exacerbated respiratory disease often get these types of reactions if they drink alcoholic beverages, such as wine or beer.

There is no specific test to diagnose the disease. Laboratory tests, such as blood tests help in looking for higher than normal levels of eosinophils, which are white blood cells. Healthcare professionals often recommend urine tests to observe inflammatory substances and elevated leukotrienes in the body.

Is Prevalence of Asthma Influencing the Aspirin Exacerbated Respiratory Disease Market

Increasing prevalence of breathing problems, such as asthma is anticipated to augur well for the global market. As per the World Health Organization (WHO), nearly 262 million people were living with asthma in 2019 and it had caused 461000 deaths. These numbers are projected to grow at a fast pace, thereby pushing the demand for aspirin exacerbated respiratory disease treatment options.

Moreover, surging awareness programs conducted by government agencies to educate the masses about the signs and symptoms of this disease is set to drive the market. Rising healthcare expenditure in both developed and developing countries across the globe is another vital factor that is likely to fuel the market.

Which Are Some of the Hindrances to the Aspirin Exacerbated Respiratory Disease Market

The diagnosis of aspirin exacerbated respiratory disease can often be delayed unless healthcare professionals have experience or expertise in recognizing and treating it. Thus, the lack of skilled healthcare professionals across emerging economies is projected to hamper the aspirin exacerbated respiratory disease market growth in future years.

What is the North America Aspirin Exacerbated Respiratory Disease Market Outlook

North America is likely to remain at the forefront by procuring the largest aspirin exacerbated respiratory disease market share in the upcoming years. The presence of numerous large-scale pharmaceutical companies in the U.S. and Canada is projected to augur well for the regional market.

The increasing consumption of zileuton (Zyflo) or montelukast (Singulair) to block the effects of leukotrienes across North America is also set to propel the market. In addition to that, patients are increasingly adopting medications, such as inhaled corticosteroids to manage asthma and it is further expected to augment the market.

How is the Asia Pacific Aspirin Exacerbated Respiratory Disease Market Progressing

Asia Pacific is likely to remain in the second position followed by North America in terms of share during the evaluation period. Rising prevalence of pollution induced asthma and the ongoing development of healthcare infrastructure in China and India are anticipated to drive the sales of aspirin exacerbated respiratory disease treatment medications.

Besides, the entry of international pharmaceutical companies in these countries owing to the availability of low-cost labor and raw material is expected to foster growth. The availability of innovative injectable medications, commonly called biologics, would also contribute to the regional market growth.

Market Competition

Some of the renowned companies operating in the global aspirin exacerbated respiratory disease market include Apotex Corporation, Pfizer Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, and Cadila Pharmaceuticals among others.

Majority of the leading companies present in the global market are increasingly focusing on mergers and acquisitions, collaborations, and joint ventures to co-develop novel products and strengthen their positions. Meanwhile, a few other key players are aiming to invest huge sums for conducting clinical trials to develop state-of-the-art medications.

Scope of Report

Report Attribute	Details
Growth Rate	CAGR of 4.9% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2015-2020
Forecast Period	2022-2032
Quantitative Units	Revenue in USD Billion, Volume in Kilotons and CAGR from 2022-2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Product Type Distribution Channel Route of Administration Region
Regions Covered	North America Latin America Western Europe Eastern Europe APEJ Japan Middle East and Africa
Key Countries Profiled	U.S Canada Brazil Argentina Germany U.K France Spain Italy Nordics BENELUX Australia & New Zealand China India ASEAN GCC South Africa
Key Companies Profiled	Apotex Corporation Pfizer Inc. Teva Pharmaceuticals Zydus Pharmaceuticals Cadila Pharmaceuticals
Customization	Available Upon Request

Key Segments Profiled in the Aspirin Exacerbated Respiratory Disease Industry Survey

By Product Type:

• Glucocorticoids
• Antihistamines
• Aspirin Desensitization

Route of Administration:

• Nasal
• Oral

By Distribution Channel:

• Hospital Pharmacy
• Retail Stores
• Online Pharmacy

By Region:

• North America
• Latin America
• Eastern Europe
• Western Europe
• Asia Pacific Excluding Japan and China
• China
• Japan
• Middle East & Africa